NCT04570423
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Chemotherapy, Other

Key Eligibility Criteria:

Gender: All
Age: 1 Month to 18 Years (Child, Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients over the age of 18 years; Patients with active central nervous system (CNS) disease
https://ClinicalTrials.gov/show/NCT04570423